InFlectis BioScience Completes Enrollment of Its Phase 2 Trial of IFB-088 for the Treatment of Amyotrophic Lateral Sclerosis; Anticipates Initial Results Later This Year

InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has completed enrollment in its Phase 2

Nantes, France--(Newsfile Corp. - January 31, 2024) - InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has completed enrollment in its Phase 2 clinical trial of IFB-088 (INN: icerguastat), a novel investigational treatment of Amyotrophic Lateral Sclerosis (ALS).

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • InFlectis completed enrollment in its Phase 2 clinical trial of IFB-088 in ALS.
  • IFB-088 is capable of crossing the blood-brain barrier and believed to act by selectively inhibiting a biomolecular switch to give cells additional time to repair or eliminate mis-folded proteins.
  • Initial findings to be reported as early as the end of 2024.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/196325_figure1_550.jpg

Click image above to view full announcement.


About InFlectis BioScience

InFlectis is a French-based drug discovery company developing first-in-class therapies for neuromuscular diseases. We are in clinical development with an orally available small molecule that has the potential to extend lives or improve the quality-of-life for people suffering from ALS and CMT, a rare and progressive hereditary nerve condition.

Contacts:

Philippe Gu’edat
philippeguedat@inflectisbioscience.com

Source: Inflectis

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/196325

MORE ON THIS TOPIC